Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Central Venous Catheter | Research

Central venous access device terminologies, complications, and reason for removal in oncology: a scoping review

Authors: Kerrie Curtis, Karla Gough, Meinir Krishnasamy, Elena Tarasenko, Geoff Hill, Samantha Keogh

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Lack of agreed terminology and definitions in healthcare compromises communication, patient safety, optimal management of adverse events, and research progress. The purpose of this scoping review was to understand the terminologies used to describe central venous access devices (CVADs), associated complications and reasons for premature removal in people undergoing cancer treatment. It also sought to identify the definitional sources for complications and premature removal reasons. The objective was to map language and descriptions used and to explore opportunities for standardisation.

Methods

A systematic search of MedLine, PubMed, Cochrane, CINAHL Complete and Embase databases was performed. Eligibility criteria included, but were not limited to, adult patients with cancer, and studies published between 2017 and 2022. Articles were screened and data extracted in Covidence. Data charting included study characteristics and detailed information on CVADs including terminologies and definitional sources for complications and premature removal reasons. Descriptive statistics, tables and bar graphs were used to summarise charted data.

Results

From a total of 2363 potentially eligible studies, 292 were included in the review. Most were observational studies (n = 174/60%). A total of 213 unique descriptors were used to refer to CVADs, with all reasons for premature CVAD removal defined in 84 (44%) of the 193 studies only, and complications defined in 56 (57%) of the 292 studies. Where available, definitions were author-derived and/or from national resources and/or other published studies.

Conclusion

Substantial variation in CVAD terminology and a lack of standard definitions for associated complications and premature removal reasons was identified. This scoping review demonstrates the need to standardise CVAD nomenclature to enhance communication between healthcare professionals as patients undergoing cancer treatment transition between acute and long-term care, to enhance patient safety and rigor of research protocols, and improve the capacity for data sharing.
Appendix
Available only for authorised users
Literature
1.
Zakhour R, Chaftari AM, Raad II. Catheter-related infections in patients with haematological malignancies: novel preventive and therapeutic strategies. Lancet Infect Dis. 2016;16(11):e241–50.PubMedCrossRef
2.
Moss JG, Wu O, Bodenham AR, Agarwal R, Menne TF, Jones BL, et al. Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial. Lancet. 2021;398(10298):403–15.PubMedCrossRef
3.
Mariggiò E, Iori AP, Micozzi A, Chistolini A, Latagliata R, Berneschi P, et al. Peripherally inserted central catheters in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer. 2020;28(9):4193–9.PubMedCrossRef
4.
Levi M, Sivapalaratnam S. An overview of thrombotic complications of old and new anticancer drugs. Thromb Res. 2020;191 Suppl 1:S17–21.PubMedCrossRef
5.
van Waart H, Stuiver MM, van Harten WH, Geleijn E, Kieffer JM, Buffart LM, et al. Effect of low-intensity physical activity and moderate- to high-intensity physical exercise during adjuvant chemotherapy on physical fitness, fatigue, and chemotherapy completion rates: results of the PACES randomized clinical trial. J Clin Oncol. 2015;33(17):1918–27.PubMedCrossRef
6.
7.
Cornet R, de Keizer N. Forty years of SNOMED: a literature review. BMC Med Inf Decis Mak. 2008;8 Suppl 1(Suppl 1):S2.CrossRef
8.
9.
Gaudet-Blavignac C, Foufi V, Bjelogrlic M, Lovis C. Use of the systematized nomenclature of medicine clinical terms (SNOMED CT) for processing free text in health care: systematic scoping review. J Med Internet Res. 2021;23(1):e24594.PubMedCrossRefPubMedCentral
10.
Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32.CrossRef
11.
Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMAScR): Checklist and Explanation. Ann Intern Med. 2018;169:467–473.
12.
Gorski L, Hadaway L, Hagle ME, McGoldrick M, Orr M, Doellman D. Infusion therapy: standards of practice. J Infus Nurs. 2016;39(1S):S1–159.CrossRef
13.
14.
15.
Aghamohammadi D, Fakhari S, Ataei Y, Bilehjani E, Jafari M. Totally implantable venous access port infection in northwest of Iran. Crescent J Med Biol Sci. 2017;4(3):126–30.
16.
Anbar R, Avci D, Cetinkaya A. Port catheter complications and thrombosis issues: assessment of 114 patients with port catheter implantation by single surgeon. Biomedical Res Therapy. 2017;4(12):1898–910.CrossRef
17.
Aribas BK, Tiken R, Aribas O, Uylar T, Akdulum I, Turker I, et al. Factors on patency periods of subcutaneous central venous Port: long-term results of 1,408 patients. Iran J Radiol. 2017;14(2):1.
18.
Bai X, Gu X, Cheng L, Yuan Q, Jing J, Jin Y, et al. Clinical diagnosis and treatment of peripherally inserted central catheter related upper extremity deep venous thrombosis. Biomedical Res (India). 2017;28(22):9707–11.
19.
Busch JD, Vens M, Herrmann J, Adam G, Ittrich H. Material failure of silicone catheter lines: a retrospective review of partial and complete ruptures in 553 patients. AJR Am J Roentgenol. 2017;208(2):464–9.PubMedCrossRef
20.
Chaftari P, Chaftari AM, Adachi J, Hachem R, Raad S, Natividad E, et al. Improvement in the diagnosis of catheter-related bloodstream infections in a tertiary cancer center. Am J Infect Control. 2017;45(3):e34–39.PubMedCrossRef
21.
Chan RJ, Northfield S, Larsen E, Mihala G, Ullman A, Hancock P, et al. Central venous access device securement and dressing effectiveness for peripherally inserted central catheters in adult acute hospital patients (CASCADE): a pilot randomised controlled trial. Trials. 2017;18(1):458.PubMedCrossRefPubMedCentral
22.
Chang DH, Mammadov K, Hickethier T, Borggrefe J, Hellmich M, Maintz D, et al. Fibrin sheaths in central venous port catheters: treatment with low-dose, single injection of urokinase on an outpatient basis. Ther Clin Risk Manag. 2017;13:111–5.PubMedCrossRefPubMedCentral
23.
Chen MH, Hwang WL, Chang KH, Chiang LCJ, Teng CLJ. Application of peripherally inserted central catheter in acute myeloid leukaemia patients undergoing induction chemotherapy. Eur J Cancer Care. 2017;26(6):e12627.CrossRef
24.
Cornillon J, Martignoles JA, Tavernier-Tardy E, Gire M, Martinez P, Tranchan C, et al. Prospective evaluation of systematic use of peripherally inserted central catheters (PICC lines) for the home care after allogeneic hematopoietic stem cells transplantation. Support Care Cancer. 2017;25(9):2843–7.PubMedCrossRef
25.
Diaz JA, Rai SN, Wu X, Chao JH, Dias AL, Kloecker GH. Phase II trial on extending the maintenance flushing interval of Implanted ports. J Oncol Pract. 2017;13(1):e22–28.PubMedCrossRef
26.
Fang S, Jiang Y, Yang J, Song L, Liu Y. Comparison of three types of central venous catheters in patients with malignant tumor receiving chemotherapy. Patient Prefer Adherence. 2017;11:1197–204.PubMedCrossRefPubMedCentral
27.
Grau D, Clarivet B, Lotthe A, Bommart S, Parer S. Complications with peripherally inserted central catheters (PICCs) used in hospitalized patients and outpatients: a prospective cohort study. Antimicrob Resist Infect Control. 2017;6:18.PubMedCrossRefPubMedCentral
28.
Hashimoto Y, Fukuta T, Maruyama J, Omura H, Tanaka T. Experience of peripherally inserted central venous catheter in patients with hematologic diseases. Intern Med (Tokyo Japan). 2017;56(4):389–93.CrossRef
29.
Hyo-Cheol K, Saebeom H, Hoyong J. Malfunction of totally implantable central venous ports. Iran J Radiol. 2017;14(1):1.
30.
Kakkos A, Bresson L, Hudry D, Cousin S, Lervat C, Bogart E, et al. Complication-related removal of totally implantable venous access port systems: does the interval between placement and first use and the neutropenia-inducing potential of chemotherapy regimens influence their incidence? A four-year prospective study of 4045 patients. Eur J Surg Oncol. 2017;43(4):689–95.PubMedCrossRef
31.
Kang J, Chen W, Sun W, Ge R, Li H, Ma E, et al. Peripherally inserted central catheter-related complications in cancer patients: a prospective study of over 50,000 catheter days. J Vasc Access. 2017;18(2):153–7.PubMedCrossRef
32.
Kang JR, Long LH, Yan SW, Wei WW, Jun HZ, Chen W. Peripherally inserted central catheter-related vein thrombosis in patients with lung cancer. Clin Appl Thromb Hemost. 2017;23(2):181–6.PubMedCrossRef
33.
Kao PF, Weng JH, Tyan YS, Yang SF, Tsao TC. The incidence of totally implantable venous access devices insertion and the associated abnormalities in patients with cancer revealed in (18)F-FDG PET-CT imaging. Acad Radiol. 2017;24(12):1588–95.PubMedCrossRef
34.
Liscynesky C, Johnston J, Haydocy KE, Stevenson KB. Prospective evaluation of peripherally inserted central catheter complications in both inpatient and outpatient settings. Am J Infect Control. 2017;45(9):1046–9.PubMedCrossRef
35.
Lo Priore E, Fliedner M, Heverhagen JT, Novak U, Marschall J. The role of a surveillance programme for intro-ducing peripherally inserted central catheters: a 2-year observational study in an academic hospital. Swiss Med Wkly. 2017;147:w14441.PubMed
36.
Longo R, Llorens M, Goetz C, Platini C, Eid N, Sellies J, et al. Taurolidine/citrate lock therapy for primary prevention of catheter-related infections in cancer patients: results of a prospective, randomized, phase IV trial (ATAPAC). Oncology. 2017;93(2):99–105.PubMedCrossRef
37.
Luong NV, Kroll MH, Vu K. Recurrence of venous thromboembolism among adults acute leukemia patients treated at the University of Texas MD Anderson cancer center: incidence and risk factors. Thromb Res. 2017;156:14–9.PubMedCrossRef
38.
Nakamura T, Sato T, Watanabe M, Sasaki J, Asari Y, Torii S. Complications after implantation of subcutaneous central venous ports (PowerPort). Annals Med Surg. 2017;17:1.CrossRef
39.
Paquet F, Boucher LM, Valenti D, Lindsay R. Impact of arm selection on the incidence of PICC complications: results of a randomized controlled trial. J. 2017;18(5):408–14.
40.
Rickard CM, Marsh NM, Webster J, Gavin NC, Chan RJ, McCarthy AL, et al. Peripherally InSerted CEntral catheter dressing and securement in patients with cancer: the PISCES trial. Protocol for a 2 × 2 factorial, superiority randomised controlled trial. BMJ Open. 2017;7(6):e015291.PubMedCrossRefPubMedCentral
41.
Seo TS, Song MG, Kim JS, Choi CW, Seo JH, Oh SC, et al. Long-term clinical outcomes of the single-incision technique for implantation of implantable venous access ports via the axillary vein. J Vasc Access. 2017;18(4):345–51.PubMedCrossRef
42.
Solinas G, Platini F, Trivellato M, Rigo C, Alabiso O, Galetto AS. Port in oncology practice: 3-monthly locking with normal saline for catheter maintenance, a preliminary report. J Vasc Access. 2017;18(4):325–7.PubMedCrossRef
43.
Tabatabaie O, Kasumova GG, Eskander MF, Critchlow JF, Tawa NE, Tseng JF. Totally implantable venous access devices: a review of complications and management strategies. Am J Clin Oncol. 2017;40(1):94–105.PubMedCrossRef
44.
Verboom MC, Ouwerkerk J, Gelderblom H, Steeghs N, Kerst JM, Lutjeboer J, et al. Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients// experience and management in a nationwide multi-center study. Clin Sarcoma Res. 2017;7(1):2.PubMedCrossRefPubMedCentral
45.
Wang YC, Lin PL, Chou WH, Lin CP, Huang CH. Long-term outcomes of totally implantable venous access devices. Support Care Cancer. 2017;25(7):2049–54.PubMedCrossRef
46.
Webster J, Larsen E, Marsh N, Choudhury A, Harris P, Rickard CM. Chlorhexidine gluconate or polyhexamethylene biguanide disc dressing to reduce the incidence of central-line-associated bloodstream infection: a feasibility randomized controlled trial (the CLABSI trial). J Hosp Infect. 2017;Date of Publication: January 29.
47.
Xie J, Xu L, Xu X, Huang Y. Complications of peripherally inserted central catheters in advanced cancer patients undergoing combined radiotherapy and chemotherapy. J Clin Nurs. 2017;26(23–24):4726–33.PubMedCrossRef
48.
Zerla PA, Canelli A, Cerne L, Caravella G, Gilardini A, De Luca G, et al. Evaluating safety, efficacy, and cost-effectiveness of PICC securement by subcutaneously anchored stabilization device. J Vasc Access. 2017;18(3):238–42.PubMedCrossRef
49.
Zhou H, Yang B, Wang C, Qin Y. Analysis and clinical significance of venography findings in complications associated with peripherally inserted central catheters. Biomedical Res (India). 2017;28(15):6619–25.
50.
Alfonso Alvarez-Rodriguez J, Garcia-Suarez M, Fernandez-Garcia D, Mendez-Martinez C, Gomez-Salgado J. Analysis of peripheral central venous access ports at the forearm: an observational study. Eur J Cancer Care. 2018;27(6):e12929.CrossRef
51.
Alkindi SY, Chai-Adisaksopha C, Cheah M, Linkins L-A. Management of cancer-associated upper extremity deep vein thrombosis with and without venous catheters at a tertiary care center. Thromb Res. 2018;166:92–5.PubMedCrossRef
52.
Bouzidi H, Emirian A, Marty A, Chachaty E, Laplanche A, Gachot B, et al. Differential time to positivity of central and peripheral blood cultures is inaccurate for the diagnosis of Staphylococcus aureus long-term catheter-related sepsis. J Hosp Infect. 2018;99(2):192–9.PubMedCrossRef
53.
Burbridge B, Plewes C, Stoneham G, Szkup P, Otani R, Babyn P, et al. Randomized clinical trial evaluating complications and complication-related removal of arm-situated power-injectable and non-power-injectable totally implanted venous access devices among cancer patients. J Vasc Interv Radiol. 2018;29(5):648–656.e3.
54.
Chaftari AM, Hachem R, Raad S, Jiang Y, Natividad E, Chaftari P, et al. Unnecessary removal of central venous catheters in Cancer patients with bloodstream infections. Infect Control Hosp Epidemiol. 2018;39(2):222–5.PubMedCrossRef
55.
Chopra V, Kaatz S, Grant P, Swaminathan L, Boldenow T, Conlon A, et al. Risk of venous thromboembolism following peripherally inserted central catheter exchange: an analysis of 23,000 hospitalized patients. Am J Med. 2018;131(6):651–60.PubMedCrossRef
56.
Davies GA, Lazo-Langner A, Gandara E, Rodger M, Tagalakis V, Louzada M, et al. A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (catheter 2). Thromb Res. 2018;162:88–92.PubMedCrossRef
57.
Decousus H, Bourmaud A, Fournel P, Bertoletti L, Labruyère C, Presles E, et al. Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP). Blood. 2018;132(7):707–16.PubMedCrossRef
58.
El-Balat A, Schmeil I, Karn T, Holtrich U, Mavrova-Risteska L, Rody A, et al. Catheter-related complications of subcutaneous implantable venous access devices in breast cancer patients. Vivo. 2018;32(5):1275–81.CrossRef
59.
Htun KT, Ma MJY, Lee AYY. Incidence and outcomes of catheter related thrombosis (CRT) in patients with acute leukemia using a platelet-adjusted low molecular weight heparin regimen. J Thromb Thrombolysis. 2018;46(3):386–92.PubMedCrossRef
60.
Imaoka Y, Kuranishi F, Ogawa Y. Usefulness of totally implantable central venous access devices in elderly patients: a retrospective study. Ann Nutr Metab. 2018;72(2):112–6.PubMedCrossRef
61.
Kato Y, Hagihara M, Kurumiya A, Takahashi T, Sakata M, Shibata Y, et al. Impact of mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI) on central line-associated bloodstream infections (CLABSIs) in department of hematology at single university hospital in Japan. J Infect Chemotherapy: Official J Japan Soc Chemother. 2018;24(1):31–5.CrossRef
62.
Kiesow L, Mahnken AH, Keulers AR. Port Implantation in patients with severe thrombocytopenia is safe with interventional radiology. Cardiovasc Interv Radiol. 2018;41(1):80–6.CrossRef
63.
Lee YM, Lee MS, Park KH, Moon C, Kim YJ, Lee HJ. Clinical impact of delayed catheter removal for patients with central-venous-catheter-related Gram-negative bacteraemia. J Hosp Infect. 2018;99(1):106–13.PubMedCrossRef
64.
Liu K, Zhou Y, Xie W, Chen X, Wang H, Gu Z, et al. Handgrip exercise reduces peripherally-inserted central catheter-related venous thrombosis in patients with solid cancers: a randomized controlled trial. Int J Nurs Stud. 2018;86:99–106.PubMedCrossRef
65.
Madabhavi I, Patel A, Anand A, Kataria P, Kadakol N, Sarkar M. Use of tunneled-cuffed central catheters in patients with cancer: a single-center experience. JAVA - J Association Vascular Access. 2018;23(1):23–9.CrossRef
66.
Madabhavi I, Patel A, Anand A, Sarkar M, Kataria P, Kadakol N. A study of the use of peripherally inserted central catheters in cancer patients: a single-center experience. J Vascular Nursing: Official Publication Soc Peripheral Vascular Nurs. 2018;36(3):149–56.CrossRef
67.
Nucci M, Braga PR, Nouer SA, Anaissie E. Time of catheter removal in candidemia and mortality. Brazilian J Infect Diseases. 2018;22(6):455–61.CrossRef
68.
Ohtake S, Nakagawa M, Uchino Y, Miura K, Iriyama N, Hatta Y, et al. 1% chlorhexidine-alcohol for preventing central venous catheter-related infection during intensive chemotherapy for patients with haematologic malignancies. J Infect Chemother. 2018;24(7):544–8.PubMedCrossRef
69.
Raad S, Chaftari AM, Hachem RY, Shah P, Natividad E, Cleeland CS, et al. Removal and insertion of central venous catheters in cancer patients is associated with high symptom burden. Expert Rev Med Dev. 2018;15(8):591–6.CrossRef
70.
Samuelson C, Kaur H, Kritsotakis EI, Goode SD, Nield A, Partridge D. A daily topical decontamination regimen reduces catheter-related bloodstream infections in haematology patients. J Infect. 2018;76(2):132–9.PubMedCrossRef
71.
Tippit D, Ananthula A, Siegel E, Ochoa D, Hill E, Merrill A, et al. Upper-extremity deep vein thrombosis in patients with breast cancer with chest versus arm central venous port catheters. Breast Cancer. 2018;12:1178223418771909.PubMedPubMedCentral
72.
Vermeulin T, Lucas M, Marini H, Di Fiore F, Loeb A, Lottin M, et al. Totally implanted venous access-associated adverse events in oncology: results from a prospective 1-year surveillance programme. Bull Cancer. 2018;105(11):1003–11.PubMedCrossRef
73.
Voog E, Bourgeois H, Domont J, Denis F, Emmanuel E, Dupuis O, et al. Totally implantable venous access ports: a prospective long-term study of early and late complications in adult patients with cancer. Support Care Cancer. 2018;26(1):81–9.PubMedCrossRef
74.
Yang S-S, Ahn MS. A comparison between upper arm and chest for optimal site of totally implanted venous access ports in patients with female breast cancer. Ann Vasc Surg. 2018;50:128–34.PubMedCrossRef
75.
Yanik F, Karamustafaoglu YA, Karatas A, Yoruk Y. Experience in totally implantable venous port catheter: analysis of 3,000 patients in 12 years. Turk gogus kalp damar cerrahisi dergisi. 2018;26(3):422–8.PubMedCrossRefPubMedCentral
76.
Zhang S, Kobayashi K, Faridnia M, Skummer P, Zhang D, Karmel MI. Clinical predictors of port infections in adult patients with hematologic malignancies. J Vascular Interventional Radiology: JVIR. 2018;29(8):1148–55.CrossRef
77.
Ahmad A, Hjerming M, Kjeldsen L, Bjerrum OW, Moser C, Classen V, et al. Hydrochloric acid prolongs the lifetime of central venous catheters in haematologic patients with bacteraemia. Dan Med J. 2019;66(5):A5544.PubMed
78.
Ammar G, Almashaikh E, Ibdah A, Shajrawi W, Awawdeh S, Al Mousa A, et al. Impact of early dressing removal on tunneled central venous catheters: a piloting study. Asian Pac J Cancer Prev. 2019;20(9):2693–7.PubMedCrossRefPubMedCentral
79.
Campagna S, Berchialla P, Gonella S, Dimonte V, Mussa B, Morano G, et al. Can peripherally inserted central catheters be safely placed in patients with Cancer receiving chemotherapy? A retrospective study of almost 400,000 catheter-days. Oncologist. 2019;24(9):e953–959.PubMedCrossRefPubMedCentral
80.
Campagna S, Gonella S, Berchialla P, Rigo C, Morano G, Zerla PA, et al. A retrospective study of the safety of over 100,000 peripherally-inserted central catheters days for parenteral supportive treatments. Res Nurs Health. 2019;42(3):198–204.PubMedCrossRef
81.
Chou PL, Fu JY, Cheng CH, Chu Y, Wu CF, Ko PJ, et al. Current port maintenance strategies are insufficient: view based on actual presentations of implanted ports. Med (Baltim). 2019;98(44):e17757.CrossRef
82.
da Costa ACC, Ribeiro JM, Vasques CI, De Luca Canto G, Porporatti AL, Dos Reis PED. Interventions to obstructive long-term central venous catheter in cancer patients: a meta-analysis. Supportive care cancer: Official J Multinational Association Supportive Care Cancer. 2019;27(2):407–21.CrossRef
83.
Fares J, Khalil M, Chaftari AM, Hachem R, Jiang Y, Kantarjian HM, et al. Impact of catheter management on clinical outcome in adult cancer patients with Gram-negative bacteremia. Open Forum Infect Dis. 2019;6(10):ofz357.PubMedCrossRefPubMedCentral
84.
Gray KL, Benson HL, Pearce CL, Steidley IG, Bachman AM, Adamski J. Implementation and 2-year outcomes of the first FDA-approved implantable apheresis vascular access device. Transfusion. 2019;59(11):3461–7.PubMedCrossRef
85.
Harrold K, Martin A, Bhuva N. A prospective audit evaluating use of urokinase in oncology patients with occluded central venous access devices. Br J Nurs. 2019;28(19):S30–36.PubMedCrossRef
86.
Hong S, Seo TS, Song MG, Seol HY, Suh SI, Ryoo IS. Clinical outcomes of totally implantable venous access port placement via the axillary vein in patients with head and neck malignancy. J Vasc Access. 2019;20(2):134–9.PubMedCrossRef
87.
Kim IJ, Shim DJ, Byeon JH, Lee JH, Kim ET, Lee HJ, et al. Impact of subcutaneous tunnels on peripherally inserted catheter placement: a multicenter retrospective study. Eur Radiol. 2019;29(5):2716–23.PubMedCrossRef
88.
Li G, Zhang Y, Ma H, Zheng J. Arm port vs chest port: a systematic review and meta-analysis. Cancer Manage Res. 2019;11:6099–112.CrossRef
89.
Nezami N, Groenwald M, Silin D, Latich I, Xing M, Kokabi N. Risk factors of infection and role of antibiotic prophylaxis in totally implantable venous access port placement: propensity score matching. Cardiovasc Interv Radiol. 2019;42(9):1302–10.CrossRef
90.
Picardi M, Della Pepa R, Cerchione C, Pugliese N, Mortaruolo C, Trastulli F, et al. A frontline approach with peripherally inserted versus centrally inserted central venous catheters for remission induction chemotherapy phase of Acute myeloid leukemia: a randomized comparison. Clin Lymphoma Myeloma Leuk. 2019;19(4):e184–194.PubMedCrossRef
91.
Ruiz-Giardin JM, Ochoa Chamorro I, Velazquez Rios L, Jaqueti Aroca J, Garcia Arata MI, SanMartin Lopez JV, et al. Blood stream infections associated with central and peripheral venous catheters. BMC Infect Dis. 2019;19(1):841.PubMedCrossRefPubMedCentral
92.
Seckold T, Walker S, Dwyer T, Signal T. Peripherally inserted central catheter postinsertion complications: a retrospective study. J Association Vascular Access. 2019;24(1):Oct–20.CrossRef
93.
Suleman A, Jarvis V, Hadziomerovic A, Carrier M, McDiarmid S. Implanted vascular access device related deep vein thrombosis in oncology patients: a prospective cohort study. Thromb Res. 2019;177:117–21.PubMedCrossRef
94.
Balsorano P, Romagnoli S, Pinelli F, Virgili G, Villa G, De Gaudio AR, et al. Peripherally inserted central catheter-related thrombosis rate in modern vascular access era-when insertion technique matters: a systematic review and meta-analysis. J Vasc Access. 2020;21(1):45–54.
95.
Bertoglio S, Cafiero F, Meszaros P, Varaldo E, Blondeaux E, Molinelli C, et al. PICC-PORT totally implantable vascular access device in breast cancer patients undergoing chemotherapy. J Vasc Access. 2020;21(4):460–6.PubMedCrossRef
96.
Calò F, Retamar P, Martínez Pérez-Crespo PM, Lanz-García J, Sousa A, Goikoetxea J, et al. Catheter-related bloodstream infections: predictive factors for Gram-negative bacteria aetiology and 30 day mortality in a multicentre prospective cohort. J Antimicrob Chemother. 2020;75(10):3056–61.PubMedCrossRef
97.
Carvalho Castanho LE, Nogueira dos Santos B, Salles Margatho A, Merizio Martins Braga FT, Diniz PE, de Oliveira MC, et al. Chlorhexidine gel dressing in hematopoietic stem cell transplantation. Acta Paulista de Enfermagem. 2020;33(3):1.
98.
Chen Y, Chen H, Yang J, Jin W, Fu D, Liu M, et al. Patterns and risk factors of peripherally inserted central venous catheter-related symptomatic thrombosis events in patients with malignant tumors receiving chemotherapy. J Vascular Surg Venous Lymphatic Disorders. 2020;8(6):919–29.CrossRef
99.
Choksi A, Finnegan K, Etezadi V. Does systemic antibiotic prophylaxis prior to the placement of totally implantable venous access devices reduce early infection? A retrospective study of 1,485 cases at a large academic institution. Am J Infect Control. 2020;48(1):95–9.PubMedCrossRef
100.
Clatot F, Fontanilles M, Lefebvre L, Lequesne J, Veyret C, Alexandru C, et al. Randomized phase II trial evaluating the safety of peripherally inserted central catheters vs implanted port catheters during adjuvant chemotherapy in early breast cancer patients. Ann Oncol. 2019;30:v739.CrossRef
101.
Dai C, Li J, Li QM, Guo X, Fan YY, Qin HY. Effect of tunneled and nontunneled peripherally inserted central catheter placement: a randomized controlled trial. J Vasc Access. 2020;21(4):511–519.
102.
de Silveira CP, Braga RC, Galvao FTMM, dos Reis CM, Ferreira PED, Clark EB. AM. Dressings for the central venous catheter to prevent infection in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis. Support Care in Cancer. 2020;28(2):425–438.
103.
de la Cruz-Hernández I, Cornejo-Juárez P, Tellez-Miranda O, Barrera-Pérez L, Sandoval-Hernández S, Vilar-Compte D, et al. Microbiology and prevalence of E2SKAPE-resistant strains in catheter-related bloodstream infections in patients with cancer. Am J Infect Control. 2020;48(1):40–5.PubMedCrossRef
104.
de Mooij CEM, van der Velden WJFM, van Groningen LFJ, Blijlevens NMA, Verweij PE, Meijer C, et al. Surveillance of catheter-related bloodstream infections in haemato-oncology patients: comparison of two definitions. J Hosp Infect. 2020;105(4):686–90.PubMedCrossRef
105.
Gudiol C, Arnan M, Aguilar-Guisado M, Royo-Cebrecos C, Sanchez-Orteg I, Montero I, et al. A randomized, double-blind, placebo-controlled trial (TAURCAT study) of citrate lock solution for prevention of endoluminal central venous catheter infection in neutropenic hematological patients. Antimicrob Agents Chemother. 2020;64(2):10.CrossRef
106.
Haggstrom L, Parmar G, Brungs D. Central venous catheter thrombosis in cancer: a multi-centre retrospective study investigating risk factors and contemporary trends in management. Clin Med Insights Oncol. 2020;14:1.17955E + 15.CrossRef
107.
Heidenreich D, Hansen E, Kreil S, Nolte F, Jawhar M, Hecht de Gutierrez A, et al. Influence of the insertion site on central venous catheter-related complications in patients undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2020;26(6):1189–94.CrossRef
108.
Ince ME, Ozkan G, Ors N, Yildirim AK, Doganci S. Complications and pitfalls of central venous port catheters: experience with 782 patients with cancer. Ir J Med Sci. 2020;189(4):1371–7.PubMedCrossRef
109.
Inoue S, Yoshida T, Nishino T, Goto M, Nishioka K, Fujimoto K, et al. Safe central venous catheters for esophageal cancer treatment. J Med Investig. 2020;67(34):298–303.CrossRef
110.
Jiang M, Cui XW, Li CL, Pan CQ, Dietrich CF. Risk of venous thromboembolism associated with totally implantable venous access ports in cancer patients: a systematic review and meta-analysis. J Thromb Haemost. 2020;18(9):2253–2273.
111.
Kao CY, Cheng YC, Chen CCC, Chai JW, Fu CH, Chen JL, et al. Outcome analysis in 270 radiologically guided implantations of totally implantable venous access ports via basilic vein. J Chin Med Association. 2020;83(3):295–301.CrossRef
112.
Kikuchi M, Sato T, Okada S, Abe N, Sato A, Suzuki Y. Maintenance antisepsis in reducing the rate of late-onset central venous catheter-related bloodstream infection: a comparison of 0.05% and 1% chlorhexidine. J Infect Chemotherapy: Official J Japan Soc Chemother. 2020;26(2):188–93.CrossRef
113.
Lingegowda D, Gehani A, Sen S, Mukhopadhyay S, Ghosh P. Centrally inserted tunnelled peripherally inserted central catheter: off-label use for venous access in oncology patients. J Vasc Access. 2020;21(5):773–7.PubMedCrossRef
114.
Low XZ, Tay KH, Leong S, Lo RHG, Zhuang KD, Chua JME, et al. Repurposing the power injectable peripherally inserted central catheter as a tunnelled, non-cuffed, centrally inserted central venous catheter in oncological patients for short- to mid-term vascular access: a pilot study. J Vasc Access. 2021;(3):457–461.
115.
Lv L, Xu J, Bai C, Gong J, Ma W, Sun X. Cluster nursing in the prevention of PICC-related venous thrombosis and its influence on tumor patients’ coagulation functions. Int J Clin Exp Med. 2020;13(12):10005–11.
116.
Malek AE, Raad II. Preventing catheter-related infections in cancer patients: a review of current strategies. Expert Rev Anti Infect Ther. 2020;18(6):531–8.PubMedCrossRef
117.
McParlan D, Edgar L, Gault M, Gillespie S, Menelly R, Reid M. Intravascular catheter migration: a cross-sectional and health-economic comparison of adhesive and subcutaneous engineered stabilisation devices for intravascular device securement. J Vasc Access. 2020;21(1):33–8.PubMedCrossRef
118.
Mielke D, Wittig A, Teichgraber U. Peripherally inserted central venous catheter (PICC) in outpatient and inpatient oncological treatment. Support care cancer. 2020;28(10):4753–60.PubMedCrossRefPubMedCentral
119.
Mollee P, Abro E, Van Kuilenburg R, Joubert W, Okano S, Looke D, et al. Catheter-associated bloodstream infections in adults with cancer: a prospective randomized controlled trial. J Hosp Infect. 2020;106(2):335–42.PubMedCrossRef
120.
Park S, Moon S, Pai H, Kim B. Appropriate duration of peripherally inserted central catheter maintenance to prevent central line-associated bloodstream infection. PLoS One. 2020;15(6):e0234966.PubMedCrossRefPubMedCentral
121.
Pu YL, Li ZS, Zhi XX, Shi YA, Meng AF, Cheng F, et al. Complications and costs of peripherally inserted central venous catheters compared with Implantable port catheters for cancer patients: a meta-analysis. Cancer Nurs. 2020;43(6):455–67.PubMedCrossRef
122.
Santacatalina-Roig E, Espinar-de Las Heras E, Ballesteros-Lizondo JM, Ibanez-Puchades I, Pescador-Marco JL. Peripherally inserted central catheter in haematopoietic stem cell transplantation. Infusion of haematopoietic cells and complications. Enfirm Clin (Engl Ed). 2020;30(5):295–301.
123.
Tan L, Sun Y, Zhu L, Lei X, Liang D, Rao N, et al. Risk factors of catheter-related thrombosis in early-stage breast cancer patients: a single-center retrospective study. Cancer Manage Res. 2019;11:8379–89.CrossRef
124.
Tang T, Li H, Wang J, Li C, Geng C. The causes and managements of catheter misplacement in implantable vascular access devices: a retrospective analysis of 8534 patients in a single center. Int J Clin Exp Med. 2019;12(9):11864–8.
125.
Taxbro K, Hammarskjöld F, Thelin B, Lewin F, Hagman H, Hanberger H, et al. Clinical impact of peripherally inserted central catheters vs implanted port catheters in patients with cancer: an open-label, randomised, two-centre trial. Br J Anaesth. 2019;122(6):734–41.PubMedCrossRef
126.
Ullman AJ, Mihala G, O’Leary K, Marsh N, Woods C, Bugden S, et al. Skin complications associated with vascular access devices: a secondary analysis of 13 studies involving 10,859 devices. Int J Nurs Stud. 2019;91:Jun–13.CrossRef
127.
Velioglu Y, Yuksel A, Sinmaz E. Complications and management strategies of totally implantable venous access port insertion through percutaneous subclavian vein. Turk Gogus kalp damar cerrahisi dergisi. 2019;27(4):499–507.PubMedCrossRefPubMedCentral
128.
Xiong ZY, Luo Z, Chen HY. Prevalence of idle peripherally inserted central catheters in adult patients: a multicenter cross-sectional study. J Vasc Access. 2019;20(6):677–82.PubMedCrossRef
129.
Yildiz A, Albayrak M, Sahin O, Pala C, Ozturk HBA, Gunes G, et al. Incidence and risk factors of port related infections in patients with hematological malignancy. Int J Clin Exp Med. 2019;12(1):989–96.
130.
Zabicki B, Limphaibool N, Veilemand Holstad MJ, Perkowska K. Central venous access ports in the interventional radiology suite - one-centre experience. Pol J Radiol. 2019;84:e328–334.PubMedCrossRefPubMedCentral
131.
Zanwar S, Gokarn A, Devadas SK, Punatar S, Khurana S, Bonda A, et al. Antibiotic lock therapy for salvage of tunneled central venous catheters with catheter colonization and catheter-related bloodstream infection. Transpl Infect Disease. 2019;21(1):e13017.CrossRef
132.
Simonetti G, Sommariva A, Lusignani M, Anghileri E, Ricci CB, Eoli M, et al. Prospective observational study on the complications and tolerability of a peripherally inserted central catheter (PICC) in neuro-oncological patients. Supportive care cancer: Official J Multinational Association Supportive Care Cancer. 2020;28(6):2789–95.CrossRef
133.
Skummer P, Kobayashi K, DeRaddo JS, Blackburn T, Schoeneck M, Patel J, et al. Risk factors for early port infections in adult oncologic patients. J Vascular Interventional Radiology: JVIR. 2020;31(9):1427–36.CrossRef
134.
Slaughter E, Keogh SJ, Kynoch K, Brodribb M. Evaluating the impact of central venous catheter materials and design on thrombosis: a systematic review and meta-analysis. Worldviews evidence-based Nurs. 2020;17(5):376–84.CrossRef
135.
Song X, Lu H, Chen F, Bao Z, Li S, Li S, et al. A longitudinal observational retrospective study on risk factors and predictive model of PICC associated thrombosis in cancer patients. Sci Rep. 2020;10(1):10090.PubMedCrossRefPubMedCentral
136.
Tang L, Kim CY, Martin JG, Pabon-Ramos WM, Sag AA, Suhocki PV, et al. Length of stay predicts risk of early infection for hospitalized patients undergoing central venous port placement. J Vascular Interventional Radiology: JVIR. 2020;31(3):454–61.PubMedCrossRef
137.
Tsuruta S, Goto Y, Miyake H, Nagai H, Yoshioka Y, Yuasa N, et al. Late complications associated with totally implantable venous access port implantation via the internal jugular vein. Supportive care cancer: Official J Multinational Association Supportive Care Cancer. 2020;28(6):2761–8.CrossRef
138.
Wang GD, Wang HZ, Shen YF, Dong J, Wang XP, Wang XZ, et al. The influence of venous characteristics on peripherally inserted central catheter-related symptomatic venous thrombosis in cancer patients. Cancer Manage Res. 2020;12:11909–20.CrossRef
139.
Yin L, Li J. Central venous catheter insertion in colorectal cancer patients, PICC or PC? Cancer Manage Res. 2020;12:5813–8.CrossRef
140.
Yin YX, Gao W, Li XY, Lu W, Deng QH, Zhao CY, et al. Randomized multicenter study on long-term complications of peripherally inserted central catheters positioned by electrocardiographic technique. Phlebology. 2020;35(8):614–622.
141.
Akhtar N, Lee L. Utilization and complications of central venous access devices in oncology patients. Curr Oncol (Toronto Ont). 2021;28(1):367–77.CrossRef
142.
Annetta MG, Ostroff M, Marche B, Emoli A, Musarò A, Celentano D, et al. Chest-to-arm tunneling: a novel technique for medium/long term venous access devices. J Vasc Access. 2023;24(1):92–8.PubMedCrossRef
143.
Clari M, Spoto M, Franceschi G, Acuto M, Tonella S, Caristia S, et al. Short versus long timing of flushing of totally implantable venous access devices when not used routinely: a systematic review and Meta-analysis. Cancer Nurs. 2021;44(3):205–213.
144.
Corti F, Brambilla M, Manglaviti S, Di Vico L, Pisanu MN, Facchinetti C, et al. Comparison of outcomes of central venous catheters in patients with solid and hematologic neoplasms: an Italian real-world analysis. Tumori. 2021;107(1):17–25.PubMedCrossRef
145.
Cruz-Aguilar R, Carney J, Mondaini V, Vehreschild M, Griskaitis M, Salmanton-García J, et al. A quality improvement study on the reduction of central venous catheter-associated bloodstream infections by use of self-disinfecting venous access caps (STERILE). Am J Infect Control. 2021;49(5):586–592.
146.
D’Souza PC, Kumar S, Kakaria A, Al-Sukaiti R, Al-Baimani K, Hamid RS, et al. Complications and management of totally implantable central venous access ports in cancer patients at a University Hospital in Oman. Sultan Qaboos Univ Med J. 2021;21(1):e103–109.PubMedCrossRefPubMedCentral
147.
Egnatios D, Gloria C. Implanted port patency: comparing heparin and normal saline. Clin J Oncol Nurs. 2021;25(2):169–73.PubMedCrossRef
148.
Kara H, Arikan AE, Dulgeroglu O, Uras C, Icten GE, Tutar B, et al. Detachment and embolization of totally implantable central venous access devices: diagnosis and management. Acta Chir Belg. 2022;122(4):240–247.
149.
Lee YM, Ryu BH, Hong SI, Cho OH, Hong KW, Bae IG, et al. Clinical impact of early reinsertion of a central venous catheter after catheter removal in patients with catheter-related bloodstream infections. Infect Control Hosp Epidemiol. 2021;42(2):162–8.PubMedCrossRef
150.
Lichtenstein T, Rau K, Hokamp NG, Maintz D, Mammadov K, Do TD, et al. Long-term follow-up and clinical relevance of incidental findings of fibrin sheath and thrombosis on computed tomography scans of cancer patients with port catheters. Ther Clin Risk Manag. 2021;17:111–8.PubMedCrossRefPubMedCentral
151.
Michell H, Nezami N, Morris C, Hong K. Dual-chambered venous access port as alternative access for extracorporeal apheresis therapy. J Vasc Access. 2021;22(2):173–7.PubMedCrossRef
152.
Sachs OA, Chugh P, He K, Moseley JM, Oneal PB, Whang E, Kristo G. Survival and Complications After Placement of Central Venous Access Ports for Palliative Chemotherapy: A Single-Institution Retrospective Analysis. The American Journal of Hospice and Palliative Care. 2022;39(1):34–38.
153.
Oh SB, Park K, Kim JJ, Oh SY, Jung KS, Park BS, et al. Safety and feasibility of 3-month interval access and flushing for maintenance of totally implantable central venous port system in colorectal cancer patients after completion of curative intended treatments. Med (Baltim). 2021;100(2):e24156.CrossRef
154.
Park EJ, Park K, Kim JJ, Oh SB, Jung KS, Oh SY, et al. Safety, efficacy, and patient satisfaction with initial peripherally inserted central catheters compared with usual intravenous access in terminally Ill cancer patients: a randomized phase II study. Cancer Res Treat. 2021;53(3):881–888.
155.
Piredda A, Radice D, Zencovich C, Cerri M, Aventino L, Naccarato F, et al. Safe use of peripherally inserted Central catheters for chemotherapy of solid malignancies in adult patients: a 1-year monocentric, prospectively-assessed, unselected cohort of 482 patients. J Vasc Access. 2020;1:E12973.
156.
Rixecker T, Lesan V, Ahlgrimm M, Thurner L, Bewarder M, Murawski N, et al. Insertion site of central venous catheter correlates with catheter-related infectious events in patients undergoing intensive chemotherapy. Bone Marrow Transplant. 2021;56(1):195–201.PubMedCrossRef
157.
Shibata J, Hiramatsu K, Shibata Y, Aoba T, Fujii M, Arimoto A, et al. Impact of chest subcutaneous fat on the occurrence of central venous port-related infectious complications in cancer patients. Support Care Cancer. 2021;29(9):5291–5398.
158.
Tumay LV, Guner OS. Availability of totally implantable venous access devices in cancer patients is high in the long term: a seven-year follow-up study. Support Care Cancer. 2021;29(7):3531–3538.
159.
Xiao MF, Xiao CQ, Li J, Dai C, Fan YY, Cao HJ, et al. Subcutaneous tunneling technique to improve outcomes for patients undergoing chemotherapy with peripherally inserted central catheters: a randomized controlled trial. J Int Med Res. 2021;49(4):3.00061E + 15.CrossRef
160.
Yan W, Zhang C, Luo C, Li Z. Management of outpatient with totally implantable venous access ports during the COVID-19 epidemic. Medicine. 2021;100(7):e24720.PubMedCrossRefPubMedCentral
161.
Sze Yong T, Vijayanathan AA, Chung E, Ng WL, Yaakup NA, Sulaiman N. Comparing catheter related bloodstream infection rate between cuffed tunnelled and non-cuffed tunnelled peripherally inserted central catheter. J Vasc Access. 2022;23(2):225–231.
162.
Gür Ö, DonbaloĞLu MO, GÜRkan S. Comparison of clinical follow-up and complications according to cancer types in patients with permanent port catheter insertion due to Malignancy. Duzce Med J. 2018;20(3):59–62.CrossRef
163.
Ban T, Fujiwara SI, Murahashi R, Nakajima H, Ikeda T, Matsuoka S, et al. Risk factors for complications associated with peripherally inserted central catheters during induction chemotherapy for acute myeloid leukemia. Intern Med. 2022;61(7):989–95.PubMedCrossRef
164.
Baumann Kreuziger L, Gaddh M, Onadeko O, George G, Wang TF, Oo TH, et al. Treatment of catheter-related thrombosis in patients with hematologic malignancies: a venous thromboEmbolism Network U.S. retrospective cohort study. Thromb Res. 2021;202:155–61.PubMedCrossRef
165.
Bertoglio S, Annetta MG, Brescia F, Emoli A, Fabiani F, Fino M, et al. A multicenter retrospective study on 4480 implanted PICC-ports: a GAVeCeLT project. J Vasc Access. 2022;24(5):1114–1120.
166.
Böll B, Schalk E, Buchheidt D, Hasenkamp J, Kiehl M, Kiderlen TR, et al. Central venous catheter-related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management, and prevention by the infectious diseases working party (AGIHO) of the German society of hematology and medical oncology (DGHO). Ann Hematol. 2021;100(1):239–59.PubMedCrossRef
167.
Brescia F, Pittiruti M, Roveredo L, Zanier C, Morabito A, Santarossa E, et al. Subcutaneously anchored securement for peripherally inserted central catheters: Immediate, early, and late complications. J Vasc Access. 2023;24(1):82–6.PubMedCrossRef
168.
Caris MG, de Jonge NA, Punt HJ, Salet DM, de Jong VMT, Lissenberg-Witte BI, et al. Indwelling time of peripherally inserted central catheters and incidence of bloodstream infections in haematology patients: a cohort study. Antimicrob Resist Infect Control. 2022;11(1):37.PubMedCrossRefPubMedCentral
169.
Chen K, Beeraka NM, Gu Y, Li J, Sinelnikov M, Han N, et al. Totally implantable venous access port systems: implant depth-based complications in breast cancer therapy - a comparative study. Curr Pharm Des. 2021;27(46):4671–6.PubMedCrossRef
170.
Chen P, Zhu B, Wan G, Qin L. The incidence of asymptomatic thrombosis related to peripherally inserted central catheter in adults: a systematic review and meta-analysis people’s. Nurs Open. 2021;8(5):2249–61.PubMedCrossRefPubMedCentral
171.
Cotogni P, Mussa B, Degiorgis C, De Francesco A, Pittiruti M. Comparative complication rates of 854 central venous access devices for home parenteral nutrition in cancer patients: a prospective study of over 169,000 catheter-days. JPEN J Parenter Enter Nutr. 2021;45(4):768–76.CrossRef
172.
El Boghdadly Z, Zhao Q, Koutou J, Lustberg ME, Ludwig M, Liscynesky C, et al. Evaluation of central line salvage for mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI) management practices in patients with hematologic malignancies. Leuk Lymphoma. 2022;63(6):1455–63.PubMedCrossRef
173.
González S, Jiménez P, Saavedra P, Macías D, Loza A, León C, et al. Five-year outcome of peripherally inserted central catheters in adults: a separated infectious and thrombotic complications analysis. Infect Control Hosp Epidemiol. 2021;42(7):833–41.PubMedCrossRef
174.
Guan X, Yan H, Zhang J, Li Y, Zhou Y. Risk factors of infection of totally implantable venous access port: a retrospective study. J Vasc Access. 2023;24(6):1340–1348.
175.
Hashimoto Y, Hosoda R, Omura H, Tanaka T. Catheter-related bloodstream infection associated with multiple insertions of the peripherally inserted central catheter in patients with hematological disorders. Sci Rep. 2021;11(1):12209.PubMedCrossRefPubMedCentral
176.
Heidenreich D, Hansen E, Kreil S, Nolte F, Jawhar M, Hecht A, et al. The insertion site is the main risk factor for central venous catheter-related complications in patients with hematologic malignancies. Am J Hematol. 2022;97(3):303–10.PubMedCrossRef
177.
178.
Johns J, Wahlrab L, Elefritz JL. Acutely ill hematology/oncology patients with central-line associated bloodstream infections and the impact of timing of catheter removal on outcomes. Am J Infect Control. 2022;50(7):749–54.PubMedCrossRef
179.
Kim TH, Choi YW, Ahn MS, Choi YS, Lee HW, Jeong SH, et al. Early removal of central venous catheter may not impact the in-hospital mortality in patients with acute leukemia. Ann Hematol. 2021;100(11):2825–30.PubMedCrossRef
180.
Kinoshita M, Takao S, Hiraoka J, Takechi K, Akagawa Y, Osaki K, et al. Risk factors for unsuccessful removal of central venous access ports implanted in the forearm of adult oncologic patients. Jpn J Radiol. 2022;40(4):412–8.PubMedCrossRef
181.
Krümpelmann U, Boseila A, Löhnert M, Kaup O, Clarenbach JJ, Görner M. An analysis of totally implantable central venous port system infections in an urban tertiary referral center. J Chemother. 2021;33(4):228–37.PubMedCrossRef
182.
Kumwenda MJ, Dougherty L, Jackson A, Hill S. Prospective audit to study urokinaSe use to restore Patency in occluded centRal venous caTheters in haematology and oncology patients (PASSPORT 2). J Vasc Access. 2021;22(4):568–74.PubMedCrossRef
183.
Liu B, Wu Z, Lin C, Li L, Kuang X. Applicability of TIVAP versus PICC in non-hematological malignancies patients: a meta-analysis and systematic review. PLoS One. 2021;16(8):e0255473.PubMedCrossRefPubMedCentral
184.
Martinez J, Capela R. Infusion pump flow rates in central venous catheters: thrombus reflux and aspiration Clot. Onconews. 2021;(42):16–20.
185.
McKeown C, Ricciuti A, Agha M, Raptis A, Hou JZ, Farah R, et al. A prospective study of the use of central venous catheters in patients newly diagnosed with acute myeloid leukemia treated with induction chemotherapy. Support Care Cancer. 2022;30(2):1673–9.PubMedCrossRef
186.
Mittal GS, Sundriyal D, Naik NB, Sehrawat A. Totally implantable venous access device (Chemoport) in Oncology: study of 168 polyurethane chemoport catheter system. South Asian J Cancer. 2021;10(4):261–4.PubMedCrossRefPubMedCentral
187.
Moralar DG, Turkmen UA, Bilen A, Turkmen S, Feyizi H, Altan HA. Our central venous port catheter system practice - a retrospective study. J Pak Med Assoc. 2021;71(5):1442–5.PubMed
188.
Pike S, Tan K, Burbridge B. Complications associated with totally implanted venous access devices in the arm versus the chest: a short-term retrospective study. Can Assoc Radiol J. 2022;73(3):581–8.PubMedCrossRef
189.
Pinelli F, Balsorano P, Mura B, Pittiruti M. Reconsidering the GAVeCeLT Consensus on catheter-related thrombosis, 13 years later. J Vasc Access. 2021;22(4):501–8.PubMedCrossRef
190.
Pinelli F, Pittiruti M, Van Boxtel T, Barone G, Biffi R, Capozzoli G, et al. GAVeCeLT-WoCoVA Consensus on subcutaneously anchored securement devices for the securement of venous catheters: current evidence and recommendations for future research. J Vasc Access. 2021;22(5):716–25.PubMedCrossRef
191.
Platanaki C, Zareifopoulos N, Lagadinou M, Tsiotsios K, Velissaris D. Correlation of positive blood cultures with peripherally inserted central catheter line infection in oncology patients. Cureus. 2021;13(1):e12858.PubMedPubMedCentral
192.
Ploton G, Brebion N, Guyomarch B, Pistorius MA, Connault J, Hersant J, et al. Predictive factors of venous recanalization in upper-extremity vein thrombosis. PLoS One. 2021;16(5):e0251269.PubMedCrossRefPubMedCentral
193.
Ranch-Lundin M, Schedin A, Björkhem-Bergman L. Equal effect of Vancomycin lock with or without heparin in treatment of central venous catheter related blood stream infections - an observational study in palliative home care. Infect Dis (Lond). 2021;53(9):719–23.PubMedCrossRef
194.
Rejane Rabelo-Silva E, Lourenço SA, Maestri RN, Candido da Luz C, Carlos Pupin V, Bauer Cechinel R, et al. Patterns, appropriateness and outcomes of peripherally inserted central catheter use in Brazil: a multicentre study of 12 725 catheters. BMJ Qual Saf. 2022;31(9):652–61.PubMedCrossRefPubMedCentral
195.
Rockholt MM, Thorarinsdottir HR, Lazarevic V, Rundgren M, Kander T. Central venous catheter-related complications in hematologic patients: an observational study. Acta Anaesthesiol Scand. 2022;66(4):473–82.PubMedCrossRef
196.
Sacks OA, Chugh P, He K, Moseley JM, Oneal PB, Whang E, et al. Survival and complications after placement of central venous access ports for palliative chemotherapy: a single-institution retrospective analysis. Am J Hosp Palliat Care. 2022;39(1):34–8.PubMedCrossRef
197.
Sapkota S, Sannur R, Naik R. Analysis of peripherally inserted central catheter line in cancer patients: a single-center experience. South Asian J Cancer. 2020;9(4):253–6.PubMedCrossRef
198.
Shih YH, Teng CJ, Chen TC, Chang KH, Chen MH. Dual-lumen power injectable peripherally inserted central catheters in allogeneic hematopoietic stem cell transplantation: a prospective observational study. J Clin Nurs. 2022;31(11–12):1654–61.PubMedCrossRef
199.
Snarski E, Stringer J, Mikulska M, Gil L, Tridello G, Bosman P, et al. Risk of infectious complications in adult patients after allogeneic hematopoietic stem cell transplantation depending on the site of central venous catheter insertion-multicenter prospective observational study, from the IDWP EBMT and Nurses Group of EBMT. Bone Marrow Transpl. 2021;56(12):2929–33.CrossRef
200.
Ullman AJ, Paterson RS, Schults JA, Kleidon TM, August D, O’Malley M, et al. Do antimicrobial and antithrombogenic peripherally inserted central catheter (PICC) materials prevent catheter complications? An analysis of 42,562 hospitalized medical patients. Infect Control Hosp Epidemiol. 2022;43(4):427–34.PubMedCrossRef
201.
Wan R, Gu L, Yin B, Cai S, Zhou R, Yang W. A six-year study of complications related to peripherally inserted central catheters: a multi-center retrospective cohort study in China. Perfusion. 2023;38(4):689–97.PubMedCrossRef
202.
Winkler MA, Spencer TR, Siddiqi N, Wallace JE, Gallien JZ, Elbalasi H, et al. Clinical experience with a chlorhexidine-coated PICC: a prospective, multicenter, observational study. J Vasc Access. 2021;25(1):225–231.
203.
Yang WJ, Song MG, Seo TS, Park SJ. Effectiveness of mechanical recanalization for intraluminal occlusion of totally implantable venous access ports. J Vasc Access. 2023;24(3):430–5.PubMedCrossRef
204.
Yun WS, Yang SS. Comparison of peripherally inserted central catheters and totally implanted venous access devices as chemotherapy delivery routes in oncology patients: a retrospective cohort study. Sci Prog. 2021;104(2):368504211011871.PubMedCrossRef
205.
Zhang Y, Zhao R, Jiang N, Shi Y, Wang Q, Sheng Y. A retrospective observational study on maintenance and complications of totally implantable venous access ports in 563 patients: prolonged versus short flushing intervals. Int J Nurs Sci. 2021;8(3):252–6.PubMedPubMedCentral
206.
Broadhurst D, Moureau N, Ullman AJ. Management of central venous Access device-Associated skin impairment: an evidence-based Algorithm. J Wound Ostomy Cont Nurs. 2017;44(3):211–20.CrossRef
207.
Busch JD, Herrmann J, Adam G, Ittrich H, Vens M, Mahler C. Complication rates observed in silicone and polyurethane catheters of totally implanted central venous Access devices implanted in the upper arm. J Vasc Interv Radiol. 2017;28(8):1177–83.PubMedCrossRef
208.
Chong HY, Lai NM, Apisarnthanarak A, Chaiyakunapruk N. Comparative efficacy of antimicrobial central venous catheters in reducing catheter-related bloodstream infections in adults: abridged cochrane systematic review and network meta-analysis. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2017;64(suppl2):S131–40.CrossRef
209.
Jones D, Wismayer K, Bozas G, Palmer J, Elliott M, Maraveyas A. The risk of venous thromboembolism associated with peripherally inserted central catheters in ambulant cancer patients. Thromb J. 2017;15:25.PubMedCrossRefPubMedCentral
210.
Kramer RD, Mann J, Rogers MAM, Saint S, Chopra V, Conte M. Are antimicrobial peripherally inserted central catheters associated with reduction in central line-associated bloodstream infection? A systematic review and meta-analysis. Am J Infect Control. 2017;45(2):108–14.PubMedCrossRef
211.
Lin WY, Lin CP, Hsu CH, Lee YH, Lin YT, Hsu MC, et al. Right or left? Side selection for a totally implantable vascular access device: a randomised observational study. Br J Cancer. 2017;117(7):932–7.PubMedCrossRefPubMedCentral
212.
Madabhavi I, Patel A, Anand A, Panchal H, Parikh S, Sarkar M. A study of Use of PORT catheter in patients with cancer: a single-center experience. Clin Med Insights: Oncol. 2017;11:1179554917691031.PubMed
213.
McDiarmid S, Scrivens N, Carrier M, Sabri E, Toye B, Huebsch L, et al. Outcomes in a nurse-led peripherally inserted central catheter program: a retrospective cohort study. CMAJ Open. 2017;5(3):E535–539.PubMedCrossRefPubMedCentral
214.
Milani A, Mazzocco K, Gandini S, Pravettoni G, Libutti L, Zencovich C, et al. Incidence and determinants of port occlusions in cancer outpatients. Cancer Nurs. 2017;40(2):102–7.PubMedCrossRef
215.
Patel PA, Boehm S, Zhou Y, Zhu C, Peterson KE, Grayes A, et al. Prospective observational study on central line-associated bloodstream infections and central venous catheter occlusions using a negative displacement connector with an alcohol disinfecting cap. Am J Infect Control. 2017;45(2):115–20.PubMedCrossRef
216.
Suleman A, McDiarmid S. A retrospective analysis of catheter-related upper extremity deep vein thrombosis in peripherally inserted catheters with and without a dermatotomy. JAVA - J Association Vascular Access. 2017;22(4):178–81.CrossRef
217.
Tabatabaie O, Kasumova GG, Kent TS, Eskander MF, Fadayomi AB, Ng SC, et al. Upper extremity deep venous thrombosis after port insertion: what are the risk factors? Surgery. 2017;162(2):437–44.PubMedCrossRef
218.
Takashima M, Ray-Barruel G, Ullman A, Keogh S, Rickard CM. Randomized controlled trials in central vascular access devices: a scoping review. PLoS One. 2017;12(3):e0174164.PubMedCrossRefPubMedCentral
219.
Voor in ’t holt AF, Helder OK, Vos MC, Schafthuizen L, Sülz S, van den Hoogen A, et al. Antiseptic barrier cap effective in reducing central line-associated bloodstream infections: a systematic review and meta-analysis. Int J Nurs Stud. 2017;69:34–40.PubMedCrossRef
220.
Wang XJ. Preventive effect of dexamethasone solution pre-treated catheter on PICC-induced phlebitis. Biomedical Res (India). 2017;28(12):5310–4.
221.
Yu L, Zhang R, Li J, Yan X, Jin K, Li W, et al. Incidence and risk factors for peripherally inserted central catheter-related vein thrombosis in lung cancer patients. Int J Clin Exp Med. 2017;10(8):12440–6.
222.
Zhang M, Kang L, Li Q. A comparative study on the use of different connectors in tube sealing in elderly tumor patients with PICC. Int J Clin Exp Med. 2017;10(6):9488–94.
223.
Brito ARO, Nishinari K, Saad PF, Saad KR, Pereira MAT, Emidio SCD, et al. Comparison between saline solution containing heparin versus saline solution in the lock of totally implantable catheters. Ann Vasc Surg. 2018;47:85–9.PubMedCrossRef
224.
Hallam C, Jackson T, Rajgopal A, Russell B. Establishing catheter-related bloodstream infection surveillance to drive improvement. J Infect Prev. 2018;19(4):160–6.PubMedCrossRefPubMedCentral
225.
Huang V. Effect of a patency bundle on central venous catheter complications among hospitalized adult patients: a best practice implementation project. JBI Database Syst Reviews Implement Rep. 2018;16(2):565–86.CrossRef
226.
Huihan Z, Yu H, Qin W, Yanping Y. Medical adhesive–related skin Injury Prevalence at the peripherally inserted central catheter insertion site: a cross-sectional, multiple-center study. J Wound Ostomy Cont Nurs. 2018;45(1):22–5.CrossRef
227.
Iftikhar R, Chaudhry QUN, Satti TM, Mahmood SK, Satti HS, Ghafoor T, et al. Noble Metal Coated Central venous catheters are not Superior to uncoated catheters in preventing infectious and non-infectious complications in immunocompromised patients. J Ayub Med Coll Abbottabad: JAMC. 2018;30(Suppl 1):S647–651.
228.
Kim JH, Hong YS, Kim SY, Kim K-P, Choi KE, Kim TW, et al. Increased incidence of chemoport-related thrombosis in patients with colorectal cancer receiving bevacizumab: a single-institutional experience. Chin J Cancer Res. 2018;30(4):460–7.PubMedCrossRefPubMedCentral
229.
Koo CM, Vissapragada R, Sharp R, Nguyen P, Ung T, Solanki C, et al. ABO blood group related venous thrombosis risk in patients with peripherally inserted central catheters. Br J Radiol. 2018;91(1082):20170560.PubMedPubMedCentral
230.
Lam PW, Volling C, Chan T, Wiggers JB, Castellani L, Wright J, et al. Impact of defaulting to single-lumen peripherally inserted central catheters on patient outcomes: an interrupted time series study. Clin Infect Dis. 2018;67(6):954–7.PubMedCrossRef
231.
Lopez-Briz E, Ruiz Garcia V, Cabello JB, Bort-Marti S, Carbonell Sanchis R, Burls A. Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults. Cochrane Database Syst Reviews. 2018;2018(7):CD008462.
232.
Lv Y, Hou Y, Yu L, Xu D, Song J, Shang H, et al. Risk associated with central catheters for malignant tumor patients: a systematic review and meta-analysis. Oncotarget. 2018;9(15):12376–88.PubMedCrossRefPubMedCentral
233.
Mansour A, Khozouz O, Saadeh SS, Abunasser M, Abdel-Razeq N, Taqash A. Clinical course and complications of catheter and non-catheter-related upper extremity deep vein thrombosis in patients with cancer. Clin Appl Thromb Hemost. 2018;24(8):1234–40.PubMedCrossRefPubMedCentral
234.
McDonald MK, Culos KA, Gatwood KS, Prow C, Chen H, Savani BN, et al. Defining incidence and risk factors for catheter-associated bloodstream infections in an outpatient adult hematopoietic cell transplantation program. Biology of blood and marrow transplantation: journal of the American Society for Blood and marrow transplantation. 2018;24(10):2081–7.PubMedCrossRef
235.
Rasero L, Golin L, Ditta S, Di Massimo DS, Dal Molin A, Piemonte G. Effects of prolonged flushing interval in totally implantable venous access devices (TIVADs). Br J Nurs. 2018;27(8):S4–10.PubMedCrossRef
236.
Spires SS, Rebeiro PF, Miller M, Koss K, Wright PW, Talbot TR. Medically attended catheter complications are common in patients with outpatient central venous catheters. Infect Control Hosp Epidemiol. 2018;39(4):439–44.PubMedCrossRefPubMedCentral
237.
Wu S, Li W, Zhang Q, Li S, Wang L. Comparison of complications between peripheral arm ports and central chest ports: a meta-analysis. J Adv Nurs. 2018;74(11):2484–96.PubMedCrossRef
238.
Yu XY, Xu JL, Li D, Jiang ZF. Late complications of totally implantable venous access ports in patients with cancer: risk factors and related nursing strategies. Medicine (Baltimore). 2018;97(38):e12427.PubMedCrossRef
239.
Agrawal SK, Gautam H, Choudhary AH, Das BK, Kumar L, Kapil A. Central line-associated bloodstream infections in cancer patients: an experience from a tertiary care cancer centre. Ind J Med Microbiol. 2019;37(3):376–80.CrossRef
240.
Bademler S, Ucuncu M, Yildirim I, Karanlik H. Risk factors for complications in cancer patients with totally implantable access ports: a retrospective study and review of the literature. J Int Med Res. 2019;47(2):702–9.PubMedCrossRef
241.
Dang FP, Li HJ, Tian JH. Comparative efficacy of 13 antimicrobial dressings and different securement devices in reducing catheter-related bloodstream infections: a bayesian network meta-analysis. Medicine (Baltimore). 2019;98(14):e14940.PubMedCrossRefPubMedCentral
242.
Dinçer M, Kocakuşak A, Hut A, Gür Ü, Çıtlak G, Akıncı M. Comparison of two different central venous Access device insertion techniques: no evil in details. Med Bull Haseki / Haseki Tip Bulteni. 2019;57(1):Sep–14.
243.
Eldeeb H, Al-Asadi O, Almusarhed M. Predictive risk factors of venous thromboembolism (VTE) associated with peripherally inserted central catheters (PICC) in ambulant solid cancer patients: retrospective single centre cohort study. Thromb J. 2019;17(1):191.
244.
Fornaro C, Piubeni M, Tovazzi V, Cosentini D, Gelmi M, Rota G, et al. Eight-week interval in flushing and locking port-a-cath in cancer patients: a single-institution experience and systematic review. Eur J Cancer Care (Engl). 2019;28(2):e12978.PubMed
245.
Fu X, Lu P, Wang C, Ye G. Analysis of the risk factors of peripherally inserted central catheter-associated venous thrombosis after chemotherapy in patients with lung cancer. Int J Clin Exp Med. 2019;12(5):5852–9.
246.
Hill S, Hamblett I, Brady S, Vasileukaya S, Zuzuarregui I, Martin F. Central venous access device-related sheaths: a predictor of infective and thrombotic incidence? Br J Nurs. 2019;28(19):S10–18.PubMedCrossRef
247.
Isom C, Bream P, Gallagher K, Walia S, Ahmed R, Kauffmann R. Placement of subcutaneous central venous ports in breast Cancer patients: does side matter? J Surg Res. 2019;244:296–301.PubMedCrossRef
248.
Kagan E, Salgado CD, Banks AL, Marculescu CE, Cantey JR. Peripherally inserted central catheter-associated bloodstream infection: risk factors and the role of antibiotic-impregnated catheters for prevention. Am J Infect Control. 2019;47(2):191–5.PubMedCrossRef
249.
Lee IJ, Kim HB, Choi YJ, Lee JH, Kim ET, Shim DJ, et al. Prevalence and predictors of peripherally inserted central catheter-associated bloodstream infections in adults: a multicenter cohort study. PLoS One. 2019;14(3):e0213555.PubMedCrossRefPubMedCentral
250.
Liu S, Cong L, Xiao Z, Song Y, Lou T, Ma Y, et al. Risk factors associated with peripherally inserted central catheter-related venous thrombosis in hospitalized patients of advanced age. J Int Med Res. 2019;48(1):300060518820744.PubMed
251.
Liu Z, Chen J, Zan L, Ding S, Yi H, Yan C. Exploring the risk factors of thrombosis and bloodstream infections in peripherally inserted central catheter (PICC) patients. J Biomaterials Tissue Eng. 2019;9(7):929–34.CrossRef
252.
Okazaki M, Oyama K, Kinoshita J, Miyashita T, Tajima H, Takamura H, et al. Incidence of and risk factors for totally implantable vascular access device complications in patients with gastric cancer: a retrospective analysis. Mol Clin Oncol. 2019;11(4):343–8.PubMedPubMedCentral
253.
Russo R, Oliveira MS, Shikanai-Yasuda MA, Mendes ET, Levin AS, Costa SF, et al. Bloodstream infection in hematopoietic stem cell transplantation outpatients: risk factors for hospitalization and death. Rev Inst Med Trop Sao Paulo. 2019;61:e3.
254.
Sengul T, Ocakci AF, Guven B, Kaya N. Connectors as a risk factor for blood-associated infections (3-way stopcock and needleless connector): a randomized-experimental study. Am J Infect Control. 2020;48(3):275–280.
255.
Skelton Iv WP, Franke AJ, Welniak S, Bosse RC, Ayoub F, Murphy M, et al. Investigation of complications following port insertion in a cancer patient population: a retrospective analysis. Clin Med Insights: Oncol. 2019;13:N.PAG–N.PAG.
256.
Suttle RD, Buffington HM, Madden WT, Dawson MA. Central line care: empowering patients to prevent infection and Injury Via EPIC2. Clin J Oncol Nurs. 2019;23(1):E10–16.PubMed
257.
Ziegler M, Landsburg D, Kucharczuk C, Gorman T, Bink K, Stadtmauer EA, et al. Fluoroquinolone prophylaxis is highly effective for the prevention of central line-associated bloodstream infections in autologous stem cell transplant patients. Biol Blood Marrow Transplant. 2019;25(5):1004–10.PubMedCrossRef
258.
Bessis S, Cassir N, Meddeb L, Remacle AB, Soussan J, Vidal V, et al. Early mortality attributable to PICC-lines in 4 public hospitals of Marseille from 2010 to 2016 (revised V3). Medicine (Baltimore). 2020;99(1):e18494.PubMedCrossRef
259.
Beypinar I, Demir H, Uysal M, Araz M, Beypinar D. The comparison of central venous port catheters in gastrointestinal cancer treatment. J Oncological Sci. 2020;6(1):10–4.CrossRef
260.
Huang W, Xu J. The role of sterile chitosan-based dressing in reducing complications related to a peripherally inserted central catheter in patients with hematological tumors. Annals Palliat Med. 2020;9(4):2037–44.CrossRef
261.
Jiang M, Li CL, Pan CQ, Yu L. The risk of bloodstream infection associated with totally implantable venous access ports in cancer patient: a systematic review and meta-analysis. Support Care Cancer. 2020;28(1):361–72.PubMedCrossRef
262.
Karapanou A, Sampanis MA, Vieru A-M, Daikos GL, Samarkos M, Pantazatou A, et al. Failure of central venous catheter insertion and care bundles in a high central line-associated bloodstream infection rate, high bed occupancy hospital. Am J Infect Control. 2020;48(7):770–6.PubMedCrossRef
263.
Kitamura H, Kimura S, Kubota Y, Komukai S, Yoshida H, Kaneko Y, et al. Venue of catheter insertion does not significantly impact the event of central line-associated bloodstream infection in patients with haematological diseases. Infect Prev Pract. 2020;2(2):100050.PubMedCrossRefPubMedCentral
264.
Kukla ME, Childs CA, Puig-Asensio M, Marra AR, Perencevich EN, Schweizer ML. Effectiveness of chlorhexidine dressings to prevent catheter-related bloodstream infections. Does one size fit all? A systematic literature review and meta-analysis. Infect Control Hosp Epidemiol. 2020;41(12):1388–1395.
265.
Lin Y, Zeng Z, Zheng J, Lin R, Liu S, Gao X. The Caprini thrombosis risk model predicts the risk of PICC-related upper extremity venous thrombosis in cancer patients. J Vasc Surg Venous Lymphat Disord. 2021;9(5):1151–1158.
266.
Liu Y, Li LL, Xu L, Feng DD, Cao Y, Mao XY, et al. Comparison between arm port and chest port for optimal vascular access port in patients with breast cancer: a systematic review and meta-analysis. Biomed Res Int. 2020;2020:9082924.PubMedPubMedCentral
267.
268.
Rowe MS, Arnold K, Spencer TR. Catheter securement impact on PICC-related CLABSI: a university hospital perspective. Am J Infect Control. 2020;48(12):1497–500.PubMedCrossRef
269.
Scrivens N, Sabri E, McDiarmid S, Bredeson C. Comparison of complication rates and incidences associated with different peripherally inserted central catheters (PICC) in patients with hematological malignancies: a retrospective cohort study. Leuk Lymphoma. 2020;61(1):156–164.
270.
Song Y, Liu S, Lou T, Ma Y, Wang N, Yong Q, et al. Risk factors associated with peripherally inserted central catheter-related venous thrombosis in hospitalized patients of advanced age. The Journal of international medical research. 2020;48(1):3.00061E + 14.CrossRef
271.
Wang G, Li Y, Wu C, Guo L, Hao L, Liao H, et al. The clinical features and related factors of PICC-related upper extremity asymptomatic venous thrombosis in cancer patients: a prospective study. Medicine. 2020;99(12):e19409.PubMedCrossRefPubMedCentral
272.
Webber JR. Sticking it to them–tissue adhesive reduces PICC Migration and microbial contamination. Vascular Access. 2020;14(1):13–7.
273.
Ying S, Liping Z, Yanhong D, Zhulin G, Liang G. Impact of arm choice for peripherally inserted central catheter (PICC) insertion on patients: a cross-sectional study. Contemp Nurse. 2020;56(1):80–9.PubMedCrossRef
274.
Chen XS, Wu XH, Chen LC, Zhang TT, Liu GL. Heparin versus 0.9% saline solution to maintain patency of totally implanted venous access ports in cancer patients: a systematic review and meta-analysis. Int J Nurs Pract. 2021;27:e12913.PubMedCrossRef
275.
Furuhashi S, Morita Y, Ida S, Muraki R, Kitajima R, Suzuki K, et al. Risk factors for totally implantable central venous access port-related infection in patients with malignancy. Anticancer Res. 2021;41(3):1547–53.PubMedCrossRef
276.
Kleidon TM, Horowitz J, Ratz D, Chopra V, Rickard CM, Ullman AJ, et al. Peripherally inserted central catheter thrombosis after Placement via Electrocardiography vs traditional methods. Am J Med. 2021;134(2):e79–88.PubMedCrossRef
277.
Rickard CM, Flynn J, Larsen E, Mihala G, Playford EG, Shaw J, et al. Needleless connector decontamination for prevention of central venous access device infection: a pilot randomized controlled trial. Am J Infect Control. 2021;49(2):269–73.PubMedCrossRef
278.
Schears GJ, Ferko N, Syed I, Arpino JM, Alsbrooks K. Peripherally inserted central catheters inserted with current best practices have low deep vein thrombosis and central line-associated bloodstream infection risk compared with centrally inserted central catheters: a contemporary meta-analysis. J Vasc Access. 2021;22(1):Sep–25.CrossRef
279.
Sharp R, Carr P, Childs J, Scullion A, Young M, Flynn T, et al. Catheter to vein ratio and risk of peripherally inserted central catheter (PICC)-associated thrombosis according to diagnostic group: a retrospective cohort study. BMJ Open. 2021;11(7):e045895.PubMedCrossRefPubMedCentral
280.
Silva SRD, Reichembach MT, Pontes L, Souza G, Kusma S. Heparin solution in the prevention of occlusions in Hickman® catheters a randomized clinical trial. Rev Latinoam Enferm. 2021;29:e3385.CrossRef
281.
Tian L, Yin X, Zhu Y, Zhang X, Zhang C. Analysis of factors causing skin damage in the application of peripherally inserted central catheter in cancer patients. J Oncol. 2021;2021:6628473.PubMedCrossRefPubMedCentral
282.
Wang G, Wang H, Shen Y, Dong J, Wang X, Wang X, et al. Association between ABO blood group and venous thrombosis related to the peripherally inserted central catheters in cancer patients. J Vasc Access. 2021;22(4):590–596.
283.
Wu X, Zhang T, Chen L, Chen X. Prolonging the flush-lock interval of totally implantable venous access ports in patients with cancer: a systematic review and meta-analysis. J Vasc Access. 2021;22(5):814–821.
284.
Xiong ZY, Zhou HM, Li SY. Prolonged flushing and locking interval for totally implantable vascular access device: a systematic review and meta-analysis. J Vasc Access. 2021;22(6):969–978.
285.
Zhang Y, Chen J, Zhao R, Zhang S. Blood sampling from peripherally inserted central catheter is effective and safe for patients with head and neck cancers. J Vasc Access. 2021;22(3):424–431.
286.
Zhong J, Wang B, Huang Q. Study on treating tumor patients with a peripherally inserted central catheter. Int J Clin Exp Med. 2021;14(1):683–9.
287.
Zhao Y, Bian L, Yang J. Intervention efficacy of MARSI nursing management on skin injury at peripherally inserted central catheter insertion site on oncological patients. Int Wound J. 2022;19(8):2055–61.PubMedCrossRefPubMedCentral
288.
Belloni S, Caruso R, Cattani D, Mandelli G, Donizetti D, Mazzoleni B, et al. Occurrence rate and risk factors for long-term central line-associated bloodstream infections in patients with cancer: a systematic review. Worldviews Evid Based Nurs. 2022;19(2):100–11.PubMedCrossRef
289.
Capozzi VA, Monfardini L, Sozzi G, Armano G, Butera D, Scarpelli E, et al. Peripherally inserted central venous catheters (PICC) versus totally implantable venous access device (PORT) for chemotherapy administration: a meta-analysis on gynecological cancer patients. Acta Biomed. 2021;92(5):e2021257.PubMedPubMedCentral
290.
Chopra V, O’Malley M, Horowitz J, Zhang Q, McLaughlin E, Saint S, et al. Improving peripherally inserted central catheter appropriateness and reducing device-related complications: a quasiexperimental study in 52 Michigan hospitals. BMJ Qual Saf. 2022;31(1):23–30.PubMedCrossRef
291.
Feng Y, Zheng R, Fu Y, Xiang Q, Yue Z, Li J, et al. Assessing the thrombosis risk of peripherally inserted central catheters in cancer patients using Caprini risk assessment model: a prospective cohort study. Support Care Cancer. 2021;29(9):5047–55.PubMedCrossRef
292.
Gilardi E, Piano A, Chellini P, Fiori B, Dolcetti L, Pittiruti M, et al. Reduction of bacterial colonization at the exit site of peripherally inserted central catheters: a comparison between chlorhexidine-releasing sponge dressings and cyano-acrylate. J Vasc Access. 2021;22(4):597–601.PubMedCrossRef
293.
He E, Ye K, Zheng H. Clinical effect and safety of venous access ports and peripherally inserted central catheters in patients receiving tumor chemotherapy: a systematic review and meta-analysis. Ann Palliat Med. 2021;10(8):9105–13.PubMedCrossRef
294.
Hoppe A, Rupa-Matysek J, Małecki B, Dytfeld D, Hoppe K, Gil L. Risk factors for catheter-related thrombosis in multiple myeloma patients undergoing autologous stem cell transplantation. Med (Kaunas). 2021;57(10):1020.
295.
Jabaley T, Xiong N, Conley S, Mazeika T, Johnson D, Biggins BA, et al. Transitioning from heparin to saline locks for central venous access devices in oncology: an evidence-based practice approach. Can Oncol Nurs J. 2022;32(2):286–93.PubMedCrossRefPubMedCentral
296.
Jones M, Okano S, Looke D, Kennedy G, Pavilion G, Clouston J, et al. Catheter-associated bloodstream infection in patients with cancer: comparison of left- and right-sided insertions. J Hosp Infect. 2021;118:70–6.PubMedCrossRef
297.
Liu GD, Ma WJ, Liu HX, Tang L, Tan YH. Risk factors associated with catheter-related venous thrombosis: a meta-analysis. Public Health. 2022;205:45–54.PubMedCrossRef
298.
Liu X, Tao S, Ji H, Chen S, Gu Y, Jin X. Risk factors for peripherally inserted central catheter (PICC)-associated infections in patients receiving chemotherapy and the preventive effect of a self-efficacy intervention program: a randomized controlled trial. Ann Palliat Med. 2021;10(9):9398–405.PubMedCrossRef
299.
Peng SY, Wei T, Li XY, Yuan Z, Lin Q. A model to assess the risk of peripherally inserted central venous catheter-related thrombosis in patients with breast cancer: a retrospective cohort study. Support Care Cancer. 2022;30(2):1127–37.PubMedCrossRef
300.
Pénichoux J, Rio J, Kammoun L, Vermeulin T, Pepin LF, Camus V, et al. Retrospective analysis of the safety of peripherally inserted catheters versus implanted port catheters during first-line treatment for patients with diffuse large B-cell lymphoma. Eur J Haematol. 2022;109(1):41–9.PubMedCrossRefPubMedCentral
301.
Perek S, Khatib A, Izhaki N, Khalaila AS, Brenner B, Horowitz NA. A prediction model for central venous catheter-related thrombosis in patients with newly-diagnosed acute myeloid leukemia: a derivation cohort analysis. Eur J Intern Med. 2022;101:68–75.PubMedCrossRef
302.
Simonetti G, Bersani A, Tramacere I, Lusignani M, Gaviani P, Silvani A. The role of body mass index in the development of thromboembolic events among cancer patients with PICCs: a systematic review. J Vasc Nurs. 2022;40(1):11–6.PubMedCrossRef
303.
Trezza C, Califano C, Iovino V, D’Ambrosio C, Grimaldi G, Pittiruti M. Incidence of fibroblastic sleeve and of catheter-related venous thrombosis in peripherally inserted central catheters: a prospective study on oncological and hematological patients. J Vasc Access. 2021;22(3):444–9.PubMedCrossRef
304.
Zhao H, He Y, Huang H, Ling Y, Zhou X, Wei Q, et al. Prevalence of medical adhesive-related skin injury at peripherally inserted central catheter insertion site in oncology patients. J Vasc Access. 2018;19(1):23–7.PubMedCrossRef
305.
306.
Schults J, Kleidon T, Chopra V, Cooke M, Paterson R, Ullman AJ, et al. International recommendations for a vascular access minimum dataset: a Delphi consensus-building study. BMJ Qual Saf. 2021;30(9);722–730.
307.
308.
Gildow C, Lazar B. The implementation of standard terminology in electronic health record systems and the effect on patient outcomes: a systematic literature review. Int J Acad Health Med Res. 2022;6(7):132–8.
309.
Gouin-Thibault I, Achkar A, Samama MM. The thrombophilic state in cancer patients. Acta Haematol. 2001;106(1–2):33–42.PubMedCrossRef
310.
Jiang D, Lee AI. Thrombotic risk from chemotherapy and other cancer therapies. In: Soff GA, editor. Thrombosis and hemostasis in cancer. Cancer treatment and research. Springer Nature; Switzerland AG. 2019.
311.
Levi M. Clinical characteristics of disseminated intravascular coagulation in patients with solid and hematological cancers. Thromb Res. 2018;164 Suppl 1:S77–81.PubMedCrossRef
312.
313.
Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infectious diseases society of America. Clin Infect Dis. 2009;49(1):1–45.PubMedCrossRef
314.
Rowley S, Clare S. Standardizing the critical clinical competency of aseptic, sterile, and clean techniques with a single international standard: Aseptic non Touch technique (ANTT®). JAVA. 2019;24(4):12–7.CrossRef
315.
Roos LL, Wall-Wieler E, Burchill C, Hamm NC, Hamad AF, Lix LM. Record linkage and big data—enhancing information and improving design. J Clin Epidemiol. 2022;150:18–24.PubMedCrossRef
Metadata
Title
Central venous access device terminologies, complications, and reason for removal in oncology: a scoping review
Authors
Kerrie Curtis
Karla Gough
Meinir Krishnasamy
Elena Tarasenko
Geoff Hill
Samantha Keogh
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12099-8

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Pulsatilla saponin D regulates ras-related C3 botulinum toxin substrate 3 (RAC3) to overcome resistance to paclitaxel in lung adenocarcinoma cells

Research

Impact of chronic obstructive pulmonary disease on the efficacy and safety of neoadjuvant immune checkpoint inhibitors combined with chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study

Research

Impact of the Sars-Cov-2 outbreak on the initial clinical presentation of new solid cancer diagnoses: a systematic review and meta-analysis

Research

Clinical features of patients with carcinoma soft tissue metastases as surgical indications: a retrospective cohort study

Research

Assessing the genomic feature of Chinese patients with ampullary adenocarcinoma: potential therapeutic targets

Systematic Review

The role of piRNAs in predicting and prognosing in cancer: a focus on piRNA-823 (a systematic review and meta-analysis)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits